Iovance Biotherapeutics develops cell therapies against cancer. Immune cells from a patient’s tumor are multiplied and returned to the patient. Its first product, Amtagvi for advanced melanoma, is approved in the US. As of Oct 16, 2026
As of Oct 16, 2026Fact sheet (from the annual report)Biotechnology and vaccines · San Carlos, USAfull fact sheet
Iovance is a biopharmaceutical company that develops and markets cell therapies against solid tumors. In central facilities, the company multiplies each patient’s own immune cells. It markets Proleukin and Amtagvi, which has accelerated approval in the United States and approval in Canada for adults with advanced melanoma after certain prior treatments, including an antibody directed against PD-1. Proleukin goes to wholesalers at home and abroad and to other customers, for example for Amtagvi treatment and research. The therapies are manufactured in its own center in Philadelphia; after all Amtagvi manufacturing was moved there, the contract with a contract manufacturer ended in the first quarter of 2026.
Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze
Price performance at a glance
Last 30 trading days
Today+5.8%
7 days−1.9%
30 days+32.6%
1 year+531.2%
Day range (last trading day)
−6.8%Price at 83% of the range+1.4%
52-week range
−87.9%Price at 94% of the range+5.4%
Distance from the all-time high
−89.6%
Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Load chart from TradingView
This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.
With a free account: save the buy zone shown for yourself (stop and targets from Watcher). It stays visible even if the zone changes later. Log in
· Sign up
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and margin
Iovance Biotherapeutics · Sector Health Care · amounts in USD
Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 24, 2026.
In short
Light red: Loss in the last fiscal year.
Light red: Profit in 0 of 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
RevenueNet incomeNet margin (below)in USD
−600M−400M−200M0200M400M
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 0.0 USD · Net income −52.9M USD · Net margin not available
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 0.0 USD · Net income −92.1M USD · Net margin not available
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 0.0 USD · Net income −123.6M USD · Net margin not available
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue not available · Net income −197.6M USD · Net margin not available
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue not available · Net income −259.6M USD · Net margin not available
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue not available · Net income −342.3M USD · Net margin not available
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue not available · Net income −395.9M USD · Net margin not available
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 1.2M USD · Net income −444.0M USD · Net margin −37,345.4%
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 164.1M USD · Net income −372.2M USD · Net margin −226.8%
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 263.5M USD · Net income −391.0M USD · Net margin −148.4%
Margin
−37,345%−227%−148%
RevenueNet incomeNet margin (below)in USD
−200M−100M0100M
Q3/23Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Revenue 469.0K USD · Net income −113.8M USD · Net margin −24,255.9%
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 482.0K USD · Net income −116.4M USD · Net margin −24,145.0% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 715.0K USD · Net income −113.0M USD · Net margin −15,800.8%
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 31.1M USD · Net income −97.1M USD · Net margin −312.2%
Q3/24Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 58.6M USD · Net income −83.5M USD · Net margin −142.7%
Q4/24Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 73.7M USD · Net income −78.6M USD · Net margin −106.6% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/25Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 49.3M USD · Net income −116.2M USD · Net margin −235.5%
Q2/25Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 60.0M USD · Net income −111.7M USD · Net margin −186.2%
Q3/25Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 67.5M USD · Net income −91.3M USD · Net margin −135.3%
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 86.8M USD · Net income −71.9M USD · Net margin −82.9% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 71.4M USD · Net income −79.0M USD · Net margin −110.7%
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 99.3M USD · Net income −47.3M USD · Net margin −47.6%
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Earnings per share not reported separately for Q4
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Earnings per share −0.19 USD
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Earnings per share −0.11 USD
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 263.5M USD · Net income −391.0M USD · Net margin −148.4%
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light gray: not available
–per year, last 3 years
Sector Health Care: median +5.1% (62 symbols)
What does this mean? Reported annual figures for a comparison over at least 3 fiscal years are missing (or the SEC data has not been fully loaded yet).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light gray: not computable
–per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: not computable (loss in the first or last year)
What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
What does this mean? Of every 100 USD in revenue there was no profit but a loss of 148.38 USD.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth
Light gray: not available
–latest balance sheet
Sector Health Care: median 0.66 (40 symbols)
What does this mean? No usable figure: reported financial debt or positive equity for the same balance sheet date is missing.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth
Light gray: none found
–Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin
Light red: 10 loss years
0 of 10fiscal years with a profit
What does this mean? In 0 of the last 10 fiscal years the bottom line showed a profit. 10 years ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
Last fiscal year and 13F
Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
263.5M USD
Revenue vs. prior year
+60.6%
Net income (FY)
−391.0M USD
Net income vs. prior year
–
EPS (FY)
-1.09 USD
13F funds with a position
–
Funds vs. prior quarter
–
Shares held vs. prior quarter
–
Fiscal year to Dec 31, 2025 · 10-K filed Feb 24, 2026 · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term).13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
Year
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
2025
Dec 31, 2025
263.5M
−391.0M
−148.4%
−1.09
–
–
2024
Dec 31, 2024
164.1M
−372.2M
−226.8%
−1.28
–
–
2023
Dec 31, 2023
1.2M
−444.0M
−37,345.4%
−1.89
–
–
2022
Dec 31, 2022
–
−395.9M
–
−2.49
–
–
2021
Dec 31, 2021
–
−342.3M
–
−2.23
–
–
2020
Dec 31, 2020
–
−259.6M
–
−1.88
–
–
2019
Dec 31, 2019
–
−197.6M
–
−1.59
–
–
2018
Dec 31, 2018
0.0
−123.6M
–
–
–
–
2017
Dec 31, 2017
0.0
−92.1M
–
–
–
–
2016
Dec 31, 2016
0.0
−52.9M
–
–
–
–
Quarters (amounts in USD, per share in USD)
Quarter
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
Q2/26
Jun 30, 2026
99.3M
−47.3M
−47.6%
−0.11
–
–
Q1/26
Mar 31, 2026
71.4M
−79.0M
−110.7%
−0.19
–
–
Q4/25*
Dec 31, 2025
86.8M
−71.9M
−82.9%
–
–
–
Q3/25
Sep 30, 2025
67.5M
−91.3M
−135.3%
−0.25
–
–
Q2/25
Jun 30, 2025
60.0M
−111.7M
−186.2%
−0.33
–
–
Q1/25
Mar 31, 2025
49.3M
−116.2M
−235.5%
−0.36
–
–
Q4/24*
Dec 31, 2024
73.7M
−78.6M
−106.6%
–
–
–
Q3/24
Sep 30, 2024
58.6M
−83.5M
−142.7%
−0.28
–
–
Q2/24
Jun 30, 2024
31.1M
−97.1M
−312.2%
−0.34
–
–
Q1/24
Mar 31, 2024
715.0K
−113.0M
−15,800.8%
−0.42
–
–
Q4/23*
Dec 31, 2023
482.0K
−116.4M
−24,145.0%
–
–
–
Q3/23
Sep 30, 2023
469.0K
−113.8M
−24,255.9%
−0.46
–
–
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary
In the last 12 months, insiders of this stock have not acquired or disposed of shares on the market (SEC Form 4).
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Trend score +90
Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+10
Relative strength+15
Volatility and trend strength
ADX 14 (trend strength)41.8
Rel. strength 60 d+234.1%
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026Yahoo Finance · Oct 27, 12:00
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026Yahoo Finance · Oct 26, 12:00
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026Finnhub · Yahoo · Oct 26, 12:00
Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026Finnhub · Benzinga · Oct 26, 08:05